Back to the Top
Hello All,
The following message was posted 4 years ago.
To All:
In routine protein binding study, one evaluates the percent of
binding in plasma. Serum differs from plasma as the fluid portion of
the blood obtained after coagulation. Hence, there is a difference in
protein components between serum and plasma. My questions to the group
are:
1. Under what circumstance or rationale if any, would one
consider doing protein binding using serum?
2. Can the expression of protein binding in plasma and serum be
comparable? That is, can one assume the value with one is a good
estimation for the other? If so, what are the justification and/or
criteria?
Thanks,
Roseline Pardue, Ph.D.
I am also looking for an answer to this exact question and was
disappointed to see no-one had replied.
Is there anyone out there who could help?
Thanks,
Hugh Abey
Novogen Ltd.
140 Wicks Rd.
North Ryde
AUSTRALIA
Back to the Top
The following message was posted to: PharmPK
Dear Roselyn
Concening your question the selection of sampling fluid (plasma or
serum) is related to analytical methods and has not pharmacokinetic
consequences.
This is based in the fact that the binding proteins (mainly albumine
and also alfa glycoprotein) are present in plasma and serum.
Serum is the fluid that remains from blood plasma after fibrinogen,
prothrombin, and other clotting factors have been removed by clot
formation and as far as I know there is not reports on drug binding
to clotting factors. Therefore, both fluids are, from the
pharmacokinetic point of view, equivalent.
Best regards
Fabiana Landoni
Back to the Top
The following message was posted to: PharmPK
In work we did about 20 years ago with salicylate protein binding,
we found a statistically significant difference in binding between
the two
blood-derived fluids. It would seem to me that plasma should be
superior
for binding studies for physiological reasons and for modeling of the
consequences of altered protein binding on pharmacokinetic and
pharmacodynamic outcomes.
Dan Sitar
Dr. Daniel Sitar
Professor and Head, Pharmacology and Therapeutics
Professor, Internal Medicine (Clinical Pharmacology)
Tel: 204-789-3532 FAX: 204-789-3932
Email: sitar.-at-.cc.umanitoba.ca
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (david@boomer.org)